BPC-157 Dosage Chart
BPC-157 (Body Protection Compound) is a 15-amino-acid pentadecapeptide derived from a sequence in human gastric juice protein. Studied extensively in rodent models for soft-tissue, tendon, and gut-barrier repair (Sikiric et al.). No human randomized controlled trials have been published as of April 2026.
Half-life
~4 hours (subcutaneous)
Format
Injectable
Purity
≥98%
Protocols
5 variants
Research Protocols
Dosage Protocols
Each row reflects a common research protocol variant. These are reference ranges derived from published literature and community research — not medical guidance.
Protocol 1
Standard Research Protocol
Dose
250-500mcg subcutaneous daily
Duration
4-6 weeks
Most commonly referenced research dose. Single morning injection or split BID (every ~12 hours) given the ~4h plasma half-life. Inject as close as practical to the target tissue when feasible.
Protocol 2
Split Dose Protocol
Dose
250mcg AM + 250mcg PM
Duration
4-6 weeks
BID dosing smooths exposure across the day. Frequently used during acute soft-tissue research windows.
Protocol 3
High-Range Research Protocol
Dose
500mcg BID (1mg/day)
Duration
3-4 weeks
Upper end of common community dosing. Limit to short windows. Sikiric preclinical work used a wide dose range; human extrapolation is not established.
Protocol 4
Maintenance Protocol
Dose
250mcg every other day
Duration
8-12 weeks
Lower-exposure variant used after an acute loading window. Often paired with TB-500 cycling.
Protocol 5
Oral Research Variant
Dose
500mcg orally daily
Duration
4-6 weeks
Oral route relevant for gut-targeted research given BPC-157's stability in gastric juice (Sikiric et al., J Physiol Pharmacol). Systemic bioavailability is uncertain.
Mixing Math
Reconstitution
Reference values for preparing a research vial. Adjust the syringe reading if you change the water volume.
Vial size
5mg vial
BAC water
2ml bacteriostatic water
Concentration
2.5mg/ml (2500mcg/ml)
Dose / ml
250mcg = 0.1ml · 500mcg = 0.2ml
Syringe units
10 IU (250mcg) · 20 IU (500mcg) on U-100
Frequently Paired
Common Stacks
Storage
Handling Notes
Lyophilized: 2-8°C preferred, -20°C for extended storage. Reconstituted: refrigerate at 2-8°C and use within 21-30 days. Protect from light. Do not freeze reconstituted solution.
Research Considerations
Cautions
- Zero published human randomized controlled trials exist. All efficacy data is preclinical, drawn primarily from the Sikiric group's rodent work.
- Not FDA approved for any human indication. Strictly a research compound.
- Local injection site reactions are common. Rotate sites and avoid repeating the same spot within 48 hours.
- Mechanism includes angiogenic and growth factor pathways. Prudent to avoid in any context with active untreated malignancy.
Ready to start your research
Get BPC-157 from Ascension Peptides
COA-verified, US-based, discreet shipping. Use code ENHANCED for 50% off your entire order.
Buy BPC-157 nowResearch use only. Not medical advice. Browse all dosage charts